deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01611259

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Conditions Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Interventions Rituximab and Lenalidomide
Updated 6 times since 2017 Last updated: Jun 19, 2017 Started: May 31, 2012 Primary completion: May 31, 2014 Completion: Feb 28, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT), this trial is completed. The trial is conducted by Arbeitsgemeinschaft medikamentoese Tumortherapie and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotCompleted~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Dec 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Dec 2017 [monthly]

    Completed PHASE2

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arbeitsgemeinschaft medikamentoese Tumortherapie
Data source: Arbeitsgemeinschaft medikamentoese Tumortherapie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations